Cabozantinib in Advanced Salivary Gland Cancer Patients

Inclusion Criteria: Disease specific * locally advanced, recurrent, and/or metastatic SGC (excluding sarcomas and mesenchymal tumors) * c-MET positive disease * Measurable disease per RECIST version 1.1 Cohort-specific criteria * SDC cohort: direct inclusion (no objective tumor growth prior to inclusion needed) * ACC cohort: inclusion after objective growth in the last three months or complaints due to the disease * Other SGC's: inclusion after objective growth in the last three months or complaints due to the disease General conditions * Age ≥18 years * Eastern Cooperative Oncology Group performance status of 0 or 1. * Normal number of neutrophils and thrombocytes * Liver function: ALT and AST \< 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN (except for Gilbert's syndrome), serum albumin ≥28 g/L * Renal function: creatinine \< 1.5 x ULN or calculated creatinine clearance ≥ 40 ml/min, Urine protein/creatinine ratio ≤113.1 mg/mmol (≤1 mg/mg) or 24-hour urine protein \<1 g * Hemoglobin A1c (HbA1c) ≤ 8% or a fasting serum glucose ≤ 9 mmol/l Exclusion Criteria: General conditions * A known allergy for cabozantinib or its components * Long QT-syndrome * Pregnancy or lactation * Patients (M/F) with reproductive potential not implementing adequate contraceptives measures * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before inclusion * Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before inclusion and from minor surgery at least 10 days before inclusion * Uncontrolled illness including, but not limited to cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias, uncontrolled hypertension defined as sustained systolic BP \> 150 mm Hg, or diastolic BP \> 100 mm Hg, stroke (including TIA), myocardial infarction, or other ischemic event within 6 months before inclusion, serious active infections Concomitant treatments * Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation. * Concurrent treatment with any other anti-cancer therapy. * Concomitant anticoagulation. Low dose aspirin for cardioprotection and low dose LMWH are permitted. * Radiation therapy within the last 4 weeks before inclusion